US6846968B1
(en)
|
1988-02-26 |
2005-01-25 |
Large Scale Biology Corporation |
Production of lysosomal enzymes in plants by transient expression
|
US5179023A
(en)
|
1989-03-24 |
1993-01-12 |
Research Corporation Technologies, Inc. |
Recombinant α-galactosidase a therapy for Fabry disease
|
IL122349A0
(en)
|
1995-06-07 |
1998-04-05 |
Univ Yale |
Adeno-associated viral vectors
|
US6458574B1
(en)
|
1996-09-12 |
2002-10-01 |
Transkaryotic Therapies, Inc. |
Treatment of a α-galactosidase a deficiency
|
AU762400B2
(en)
|
1996-09-13 |
2003-06-26 |
Shire Human Genetic Therapies, Inc. |
Therapy for alpha-galactosidase a deficiency
|
US6083725A
(en)
|
1996-09-13 |
2000-07-04 |
Transkaryotic Therapies, Inc. |
Tranfected human cells expressing human α-galactosidase A protein
|
EP0935651B1
(en)
|
1996-09-13 |
2004-12-29 |
Transkaryotic Therapies, Inc. |
THERAPY FOR alpha-GALACTOSIDASE A DEFICIENCY
|
US20020082224A1
(en)
|
1997-01-14 |
2002-06-27 |
Douglas J. Jolly |
Non-immunogenic prodrugs and selectable markers for use in gene therapy
|
GB9708526D0
(en)
|
1997-04-25 |
1997-06-18 |
Royal Free Hosp School Med |
Eukaryotic gene expression cassette and uses thereof
|
US6210666B1
(en)
|
1997-10-21 |
2001-04-03 |
Orphan Medical, Inc. |
Truncated α-galactosidase A to treat fabry disease
|
DE69835367T2
(de)
|
1997-10-29 |
2007-08-02 |
Genzyme Corp., Framingham |
Gentherapie für gaucher-krankheit
|
EP1658857A1
(en)
|
1997-10-29 |
2006-05-24 |
Genzyme Corporation |
Compositions and methods for treating lysosomal storage disease
|
US6607879B1
(en)
|
1998-02-09 |
2003-08-19 |
Incyte Corporation |
Compositions for the detection of blood cell and immunological response gene expression
|
CA2319212A1
(en)
|
1998-02-17 |
1999-08-19 |
Genzyme Corporation |
Methods for purified aav vector production
|
WO1999057296A1
(en)
|
1998-05-01 |
1999-11-11 |
Genzyme Corporation |
Partially deleted adenoviral vectors
|
US6274597B1
(en)
|
1998-06-01 |
2001-08-14 |
Mount Sinai School Of Medicine Of New York University |
Method of enhancing lysosomal α-Galactosidase A
|
US20020065236A1
(en)
|
1998-09-09 |
2002-05-30 |
Yew Nelson S. |
CpG reduced plasmids and viral vectors
|
US20090042283A1
(en)
|
1998-09-29 |
2009-02-12 |
Shire Human Genetic Therapies, Inc., A Delaware Corporation |
Optimized messenger rna
|
AU2004242550B2
(en)
|
1999-03-11 |
2008-04-03 |
Shire Human Genetic Therapies, Inc. |
Treatment of alpha-Galactosidase A deficiency
|
GB9909066D0
(en)
|
1999-04-20 |
1999-06-16 |
Oxford Glycosciences Uk Ltd |
Therapies
|
US7927587B2
(en)
|
1999-08-05 |
2011-04-19 |
Regents Of The University Of Minnesota |
MAPC administration for the treatment of lysosomal storage disorders
|
EP2275559A3
(en)
|
1999-09-28 |
2011-03-23 |
Shire Human Genetic Therapies, Inc. |
Optimized messenger RNA
|
WO2002064799A2
(en)
|
1999-09-28 |
2002-08-22 |
Transkaryotic Therapies, Inc. |
Optimized messenger rna
|
AU1997901A
(en)
|
1999-11-05 |
2001-05-14 |
Jena Bioscience Gmbh |
Protein expression systems for non-pathogenic kinetoplastidae
|
ES2284545T3
(es)
|
1999-11-16 |
2007-11-16 |
Genzyme Corporation |
Vectores y transgenes con elementos reguladores para la administracion de genes del higado.
|
EP1246915A2
(en)
|
1999-12-30 |
2002-10-09 |
Maxygen Aps |
Improved lysosomal enzymes and lysosomal enzyme activators
|
AU2001236713A1
(en)
|
2000-02-17 |
2001-08-27 |
Genzyme Corporation |
Methods for treatment of lysosomal storage diseases
|
US20010036454A1
(en)
|
2000-02-17 |
2001-11-01 |
Chester Li |
Genetic modification of the lung as a portal for gene delivery
|
US20020081654A1
(en)
|
2000-04-07 |
2002-06-27 |
Sandrin Mauro Sergio |
Targeting hydrolase enzymes
|
US20040204379A1
(en)
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
US20020095135A1
(en)
|
2000-06-19 |
2002-07-18 |
David Meeker |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
US20020014242A1
(en)
|
2000-07-31 |
2002-02-07 |
Abraham Scaria |
Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
|
EP1624067A3
(en)
|
2000-09-18 |
2006-03-15 |
Genzyme Corporation |
Expression vectors containing hybrid ubiquitin promoters
|
EP1319082B1
(en)
|
2000-09-18 |
2005-11-16 |
Genzyme Corporation |
Expression vectors containing hybrid ubiquitin promoters
|
CA2425732A1
(en)
|
2000-10-11 |
2002-08-22 |
Transkaryotic Therapies, Inc. |
Optimized messenger rna
|
US7723296B2
(en)
|
2001-01-18 |
2010-05-25 |
Genzyme Corporation |
Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
|
CA2448120A1
(en)
|
2001-05-24 |
2002-11-28 |
Genzyme Corporation |
Muscle-specific expression vectors
|
JP4742191B2
(ja)
|
2001-06-14 |
2011-08-10 |
独立行政法人産業技術総合研究所 |
糖蛋白質およびその製造方法
|
US7063962B2
(en)
|
2001-07-20 |
2006-06-20 |
Novozymes A/S |
DNA sequences for regulating transcription
|
US6749851B2
(en)
|
2001-08-31 |
2004-06-15 |
Clearant, Inc. |
Methods for sterilizing preparations of digestive enzymes
|
US20030064000A1
(en)
|
2001-09-24 |
2003-04-03 |
Wilson Burgess |
Methods of sterilizing biological mixtures using stabilizer mixtures
|
US6783968B2
(en)
|
2001-09-24 |
2004-08-31 |
Clearant, Inc. |
Methods for sterilizing preparations of glycosidases
|
US6723551B2
(en)
|
2001-11-09 |
2004-04-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Production of adeno-associated virus in insect cells
|
EP1336411A1
(en)
|
2002-02-14 |
2003-08-20 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam |
Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases
|
US20040258678A1
(en)
|
2002-02-22 |
2004-12-23 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
ES2367257T3
(es)
|
2002-04-25 |
2011-10-31 |
Shire Human Genetic Therapies, Inc. |
Tratamiento de deficit de alfa-galactosidasa a.
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
US7807618B2
(en)
|
2002-05-20 |
2010-10-05 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone and other tissues
|
WO2003101202A1
(en)
|
2002-05-31 |
2003-12-11 |
Osiris Therapeutics, Inc. |
Intraperitoneal delivery of genetically engineered mesenchymal stem cells
|
US20030224477A1
(en)
|
2002-05-31 |
2003-12-04 |
Heartlein Michael W. |
Optimized promoter constructs
|
US20060263774A1
(en)
|
2002-11-01 |
2006-11-23 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
AU2003302386B2
(en)
|
2002-11-26 |
2010-04-01 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US20040248262A1
(en)
|
2003-01-22 |
2004-12-09 |
Koeberl Dwight D. |
Constructs for expressing lysomal polypeptides
|
PT2444102E
(pt)
|
2003-01-31 |
2015-09-17 |
Sinai School Medicine |
Terapia combinada para o tratamento de distúrbios de deficiência proteica
|
US7446098B2
(en)
|
2003-02-18 |
2008-11-04 |
Mount Sinai School Of Medicine Of New York University |
Combination therapy for treating protein deficiencies
|
EP1606313A2
(en)
|
2003-03-19 |
2005-12-21 |
Isogenis, Inc. |
Specific inhibition of allograft rejection
|
US7951557B2
(en)
|
2003-04-27 |
2011-05-31 |
Protalix Ltd. |
Human lysosomal proteins from plant cell culture
|
US20100196345A1
(en)
|
2003-04-27 |
2010-08-05 |
Protalix |
Production of high mannose proteins in plant culture
|
PL1620133T3
(pl)
|
2003-05-01 |
2016-05-31 |
Genzyme Corp |
Terapia genowa dla zaburzeń neurometabolicznych
|
WO2004098532A2
(en)
|
2003-05-05 |
2004-11-18 |
Genzyme Corporation |
Methods of reducing an immune response
|
DK2332972T3
(en)
|
2003-06-24 |
2018-04-23 |
Genzyme Corp |
Hitherto UNKNOWN BETA-ACTIN AND RPS21 PROMOTORS AND APPLICATIONS
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
JP2007513188A
(ja)
|
2003-12-04 |
2007-05-24 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
リソソーム蓄積症の処置のための組成物および方法
|
WO2005074888A2
(en)
|
2004-02-03 |
2005-08-18 |
Biodelivery Sciences International, Inc. |
Replacement enzyme cochleates
|
WO2005077093A2
(en)
|
2004-02-06 |
2005-08-25 |
Biomarin Pharmaceutical Inc. |
Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
|
US20050208090A1
(en)
|
2004-03-18 |
2005-09-22 |
Medtronic, Inc. |
Methods and systems for treatment of neurological diseases of the central nervous system
|
WO2006007560A2
(en)
|
2004-07-01 |
2006-01-19 |
University Of Pennsylvania |
Targeted protein replacement for the treatment of lysosomal storage disorders
|
US7892809B2
(en)
|
2004-12-15 |
2011-02-22 |
The University Of North Carolina At Chapel Hill |
Chimeric vectors
|
EP3058959B1
(en)
|
2005-05-02 |
2019-01-30 |
Genzyme Corporation |
Gene therapy for neurometabolic disorders
|
US8500720B2
(en)
|
2005-05-09 |
2013-08-06 |
Medtronic, Inc |
Method and apparatus for treatment of cardiac disorders
|
US20110070201A1
(en)
|
2005-07-18 |
2011-03-24 |
Protalix Ltd. |
Mucosal or enteral administration of biologically active macromolecules
|
WO2007053565A2
(en)
|
2005-10-31 |
2007-05-10 |
Zymequest, Inc. |
Novel a-galactosidases
|
US7935336B2
(en)
|
2005-11-18 |
2011-05-03 |
Tokyo Metropolitan Organization For Medical Research |
Highly functional enzyme having α-galactosidase activity
|
AR059089A1
(es)
|
2006-01-20 |
2008-03-12 |
Genzyme Corp |
Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
|
WO2007089632A2
(en)
|
2006-01-27 |
2007-08-09 |
The University Of North Carolina At Chapel Hill |
Heparin and heparan sulfate binding chimeric vectors
|
AR059371A1
(es)
|
2006-02-08 |
2008-03-26 |
Genzyme Corp |
Terapia genica para la enfermedad de niemann-pick tipo a
|
MX361816B
(es)
|
2006-02-09 |
2018-12-17 |
Genzyme Corp |
Suministro intraventricular lento.
|
WO2007137072A2
(en)
|
2006-05-16 |
2007-11-29 |
Amicus Therapeutics, Inc. |
Assays for diagnosing and evaluating treatment options for fabry disease
|
WO2008075957A1
(en)
|
2006-12-21 |
2008-06-26 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Treatment of fabry disease
|
CN101631794B
(zh)
|
2007-01-18 |
2013-01-02 |
建新公司 |
包含氨基氧基基团的寡糖及其轭合物
|
CA2584494A1
(en)
|
2007-03-27 |
2008-09-27 |
Jeffrey A. Medin |
Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
|
JP2010523578A
(ja)
|
2007-03-30 |
2010-07-15 |
アミカス セラピューティックス インコーポレイテッド |
薬理シャペロンを用いるファブリー病の治療方法
|
US9999618B2
(en)
|
2007-04-26 |
2018-06-19 |
Amicus Therapeutics, Inc. |
Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
|
AU2008245578A1
(en)
|
2007-04-26 |
2008-11-06 |
Amicus Therapeutics, Inc. |
Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
|
HUE035779T2
(en)
|
2007-06-06 |
2018-05-28 |
Genzyme Corp |
Gene therapy for lysosomal storage disorders
|
WO2009032171A1
(en)
|
2007-08-29 |
2009-03-12 |
Shire Human Genetic Therapies, Inc. |
Subcutaneous administration of alpha-galatosidase a
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
WO2009066069A1
(en)
|
2007-11-21 |
2009-05-28 |
Summit Corporation Plc |
Treatment of protein folding disorders
|
WO2009097129A1
(en)
|
2008-01-29 |
2009-08-06 |
Applied Genetic Technologies Corporation |
Recombinant virus production using mammalian cells in suspension
|
EP2946785B1
(en)
|
2008-02-12 |
2018-10-24 |
Amicus Therapeutics, Inc. |
Method to predict response to pharmacological chaperone treatment of diseases
|
US8568709B2
(en)
|
2008-03-20 |
2013-10-29 |
University Health Network |
Thymidylate kinase fusions and uses thereof
|
US8632764B2
(en)
|
2008-04-30 |
2014-01-21 |
University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
CA3004867C
(en)
|
2008-06-26 |
2020-09-15 |
Orphazyme Aps |
Use of hsp70 as a regulator of enzymatic activity
|
WO2010015816A2
(en)
|
2008-08-06 |
2010-02-11 |
Summit Corporation Plc |
Treatment of lysosomal storage disorders and other proteostatic diseases
|
PL2465542T3
(pl)
|
2008-12-16 |
2015-06-30 |
Genzyme Corp |
Koniugaty białko-oligosacharyd
|
US8889641B2
(en)
|
2009-02-11 |
2014-11-18 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
GB0911870D0
(en)
|
2009-07-08 |
2009-08-19 |
Ucl Business Plc |
Optimised coding sequence and promoter
|
US20120195876A1
(en)
|
2009-08-14 |
2012-08-02 |
Jochen Reiser |
Novel role of alpha-galactosidase activity as a biomarker in kidney disease
|
JP5990102B2
(ja)
|
2009-09-29 |
2016-09-07 |
ユニフェルシテイト ヘント |
ホスホ−6−マンノースへのマンノース−1−ホスホ−6−マンノース結合の加水分解
|
CN102781965A
(zh)
|
2009-10-06 |
2012-11-14 |
安吉奥开米公司 |
用于转运治疗剂的组合物和方法
|
EP2493487B1
(en)
|
2009-10-27 |
2016-08-24 |
Erytech Pharma |
Composition to induce specific immune tolerance
|
WO2011057243A2
(en)
|
2009-11-09 |
2011-05-12 |
University Of Central Florida Research Foundation, Inc. |
Administration of plant expressed oral tolerance agents
|
US9194011B2
(en)
|
2009-11-17 |
2015-11-24 |
Protalix Ltd. |
Stabilized alpha-galactosidase and uses thereof
|
WO2011061736A1
(en)
|
2009-11-17 |
2011-05-26 |
Protalix Ltd. |
Alkaline alpha galactosidase for the treatment of fabry disease
|
SI2796457T1
(sl)
|
2009-11-27 |
2016-10-28 |
Genzyme Corporation |
Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji
|
WO2011088081A1
(en)
|
2010-01-12 |
2011-07-21 |
The University Of North Carolina At Chapel Hill |
Restrictive inverted terminal repeats for viral vectors
|
NZ623294A
(en)
|
2010-03-02 |
2015-10-30 |
Protalix Ltd |
Stabilized alpha-galactosidase and uses thereof
|
RU2612788C2
(ru)
|
2010-03-23 |
2017-03-13 |
Интрексон Корпорейшн |
Векторы, условно экспрессирующие терапевтические белки, клетки-хозяева, содержащие указанные векторы, и их применение
|
US8809282B2
(en)
|
2010-05-06 |
2014-08-19 |
Duke University |
Method of reducing titers of antibodies specific for a therapeutic agent
|
ES2650689T3
(es)
|
2010-06-25 |
2018-01-19 |
Shire Human Genetic Therapies, Inc. |
Administración de agentes terapéuticos al sistema nervioso central
|
CN103154263A
(zh)
|
2010-08-19 |
2013-06-12 |
诺维信公司 |
诱导的孢子形成筛选方法
|
SG189108A1
(en)
|
2010-09-29 |
2013-05-31 |
Oxyrane Uk Ltd |
Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
JP5913372B2
(ja)
|
2011-01-20 |
2016-04-27 |
プロタリクス リミテッド |
植物および植物細胞におけるα−ガラクトシダーゼの発現のための核酸発現構築物
|
CN107088225A
(zh)
|
2011-03-11 |
2017-08-25 |
阿米库斯治疗学公司 |
治疗法布里病的给药方案
|
DK2691529T3
(da)
|
2011-03-31 |
2019-09-23 |
Univ Iowa Res Found |
AAV2-partikel omfattende et AAV2-kapsidprotein og en vektor omfattende en nukleinsyre, der koder for en tripeptidylpeptidase 1 (TPP1) til anvendelse til behandling af sen infantil ceroid lipofuscinose (LINCL) hos et ikke-gnaver pattedyr ved intraventrikulær injektion eller ICV-indgivelse
|
US20120283290A1
(en)
|
2011-05-06 |
2012-11-08 |
Amicus Therapeutics Inc. |
Quantitation of gl3 in urine
|
BR112013031553A2
(pt)
|
2011-06-08 |
2020-11-10 |
Shire Human Genetic Therapies, Inc. |
composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
|
KR102076585B1
(ko)
|
2011-12-22 |
2020-02-12 |
센토제너 아이피 게엠베하 |
리소좀 효소를 재배열하는 능력을 갖는 화합물 및 암브록솔 및/또는 암브록솔의 유도체의 조합물
|
SG10201609345QA
(en)
|
2012-02-07 |
2017-01-27 |
Global Bio Therapeutics Inc |
Compartmentalized method of nucleic acid delivery and compositions and uses thereof
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
JP6283655B2
(ja)
|
2012-03-29 |
2018-02-21 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
イオン化可能なカチオン性脂質
|
AU2013243949A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
AU2013243946A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of membrane proteins
|
DK2839001T3
(en)
|
2012-04-18 |
2017-12-11 |
Vib Vzw |
METHODS AND PROCEDURES FOR THE PREPARATION OF IMPROVED PROTEINS
|
US11911487B2
(en)
|
2012-05-03 |
2024-02-27 |
Indiana University Research And Technology Corporation |
Hydrodynamic methods for delivering fluids to kidney tissues and related materials and methods
|
WO2013181454A1
(en)
|
2012-05-30 |
2013-12-05 |
Biostrategies LC |
Plant lectins as carriers of associated drug substances into animal and human cells
|
WO2014011237A1
(en)
|
2012-07-11 |
2014-01-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for the treatment of lysosomal storage diseases
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
EP2874648A4
(en)
|
2012-07-17 |
2015-12-30 |
Amicus Therapeutics Inc |
CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN
|
GB201213117D0
(en)
|
2012-07-24 |
2012-09-05 |
Ucl Business Plc |
Transgene expression
|
WO2014017915A2
(en)
|
2012-07-27 |
2014-01-30 |
Universiteit Utrecht Holding B.V. |
Urea and guanidinium derivatives of iminosugars
|
CA2880162C
(en)
|
2012-07-31 |
2023-04-04 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
US10138474B2
(en)
|
2012-08-17 |
2018-11-27 |
Research Foundation Of The City University Of New York |
Scavenger receptor uptake for fabry disease enzyme replacement therapy
|
US20150366997A1
(en)
|
2012-12-07 |
2015-12-24 |
Shire Human Genetics Therapies, Inc. |
COMPOSITIONS AND METHODS FOR mRNA DELIVERY
|
WO2014120900A1
(en)
|
2013-01-31 |
2014-08-07 |
Icahn School Of Medicine At Mount Sinai |
Enhanced therapeutic regimens for treating fabry disease
|
AU2014244167A1
(en)
|
2013-03-13 |
2015-10-08 |
The Children's Hospital Of Philadelphia |
Adeno-associated virus vectors and methods of use thereof
|
EP3750903A1
(en)
|
2013-03-14 |
2020-12-16 |
Translate Bio, Inc. |
Ribonucleic acids with 4'-thio-modified nucleotides and related methods
|
JP6506250B2
(ja)
|
2013-03-15 |
2019-04-24 |
アミカス セラピューティックス インコーポレイテッド |
化学架橋剤
|
US9447433B2
(en)
|
2013-03-15 |
2016-09-20 |
The University Of North Carolina At Chapel Hill |
Synthetic adeno-associated virus inverted terminal repeats
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
KR20220119187A
(ko)
|
2013-05-15 |
2022-08-26 |
리젠츠 오브 더 유니버시티 오브 미네소타 |
중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
|
WO2014201252A2
(en)
|
2013-06-13 |
2014-12-18 |
Shire Human Genetic Therapies, Inc. |
Messenger rna based viral production
|
US20140377246A1
(en)
|
2013-06-19 |
2014-12-25 |
Carol Ann Foundation and International Morquio Organization |
Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme
|
CA2918902C
(en)
|
2013-07-26 |
2023-04-04 |
University Of Iowa Research Foundation |
Methods and compositions for treating brain diseases
|
DK3033102T4
(da)
|
2013-08-13 |
2024-02-26 |
Univ Northwestern |
Peptidkonjugerede partikler
|
TW202332774A
(zh)
|
2013-10-23 |
2023-08-16 |
美商健臻公司 |
重組醣蛋白及其用途
|
EP3060669A1
(en)
|
2013-10-24 |
2016-08-31 |
uniQure IP B.V. |
Aav-5 pseudotyped vector for gene therapy for neurological diseases
|
US10233216B2
(en)
|
2013-11-15 |
2019-03-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for suppression of inhibitor formation against coagulation factors in hemophilia patients
|
US20160361301A1
(en)
|
2013-12-11 |
2016-12-15 |
Genzyme Corporation |
Glucosylceramide synthase inhibitors
|
CN105828811B
(zh)
|
2013-12-23 |
2022-04-08 |
Bcn肽类股份有限公司 |
用于在溶酶体贮积症或糖原贮积病的治疗中使用的作为胞吐作用活化化合物的比卡鲁胺类似物或(s)-比卡鲁胺
|
WO2015119989A1
(en)
|
2014-02-04 |
2015-08-13 |
New York University |
Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases
|
CN114231563A
(zh)
|
2014-05-02 |
2022-03-25 |
建新公司 |
用于视网膜及cns基因疗法的aav载体
|
JP6652334B2
(ja)
|
2014-05-31 |
2020-02-19 |
Jcrファーマ株式会社 |
ウリジンとn−アセチル−d−マンノサミンとを含有する培地
|
CN106714826A
(zh)
|
2014-09-07 |
2017-05-24 |
西莱克塔生物科技公司 |
用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物
|
EP3218000A2
(en)
|
2014-11-10 |
2017-09-20 |
Alexion Pharmaceuticals, Inc. |
Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof
|
US20170130205A1
(en)
|
2014-11-21 |
2017-05-11 |
Taipei Veterans General Hospital |
Method for preparing induced pluripotent stem cells
|
DE202015009961U1
(de)
|
2014-12-12 |
2022-01-25 |
Curevac Ag |
Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
LT3237621T
(lt)
|
2014-12-22 |
2023-09-25 |
Codexis, Inc. |
Žmogaus alfa-galaktozidazės variantai
|
CA2966092A1
(en)
|
2014-12-30 |
2016-07-07 |
Curevac Ag |
Artificial nucleic acid molecules
|
JP6938377B2
(ja)
|
2015-01-14 |
2021-09-22 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
標的化遺伝子移入のための方法および組成物
|
US10350245B2
(en)
|
2015-01-21 |
2019-07-16 |
Fred Hutchinson Cancer Research Center |
Point-of-care and/or portable platform for gene therapy
|
MX2017010370A
(es)
|
2015-02-10 |
2017-12-14 |
Genzyme Corp |
Suministro mejorado de particulas virales al cuerpo estriado y al cortex.
|
CN107250365A
(zh)
|
2015-02-19 |
2017-10-13 |
丹尼斯科美国公司 |
增强的蛋白质表达
|
US20180135074A1
(en)
|
2015-02-19 |
2018-05-17 |
University Of Florida Research Foundation, Incorporated |
Recombinant aav vectors for gene therapy of human hematopoietic disorders
|
MX2017011510A
(es)
|
2015-03-17 |
2018-01-11 |
Greenovation Biotech Gmbh |
Proteinas lisosomales glicosiladas, metodo de produccion y usos.
|
US10883117B2
(en)
|
2015-03-24 |
2021-01-05 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
WO2016154313A1
(en)
|
2015-03-24 |
2016-09-29 |
Zywie, Llc |
High drug loading liquid oral pharmaceutical compositions
|
US9981021B1
(en)
|
2015-04-09 |
2018-05-29 |
Kinetiq, Inc. |
Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
|
US11020443B2
(en)
|
2015-04-23 |
2021-06-01 |
University Of Massachusetts |
Modulation of AAV vector transgene expression
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
AU2016263119B2
(en)
|
2015-05-15 |
2021-08-12 |
Regents Of The University Of Minnesota |
Adeno-associated for therapeutic delivery to central nervous system
|
AU2016271519B2
(en)
|
2015-06-05 |
2021-09-02 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for transient gene therapy with enhanced stability
|
US20180185415A1
(en)
|
2015-07-01 |
2018-07-05 |
The Regents Of The University Of California |
Retroviral vectors containing a reverse orientation human ubiquitin c promoter
|
US11390656B2
(en)
|
2015-08-04 |
2022-07-19 |
New York University |
Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
|
US20170051267A1
(en)
|
2015-08-20 |
2017-02-23 |
Research Foundation Of The City University Of New York |
Novel alpha-galactosidase a derivatives
|
WO2017049161A1
(en)
|
2015-09-18 |
2017-03-23 |
Duke University |
ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER
|
EP3782639B1
(en)
|
2015-12-08 |
2022-07-20 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
US11124546B2
(en)
|
2015-12-14 |
2021-09-21 |
The University Of North Carolina At Chapel Hill |
Modified capsid proteins for enhanced delivery of parvovirus vectors
|
GB201522243D0
(en)
|
2015-12-16 |
2016-01-27 |
Ucl Business Plc |
Treatment
|
EP3380496B1
(en)
|
2015-12-23 |
2020-05-20 |
Danisco US Inc. |
Enhanced protein production and methods thereof
|
WO2017120222A1
(en)
|
2016-01-04 |
2017-07-13 |
Cour Pharmaceuticals Development Company Inc. |
Particles encapsulating fusion proteins containing linked epitopes
|
WO2017122093A1
(en)
|
2016-01-11 |
2017-07-20 |
Medgenics Medical Israel Ltd. |
Compositions and methods for treatment of central nervous system diseases
|
AR107483A1
(es)
|
2016-01-29 |
2018-05-02 |
Hanmi Pharm Ind Co Ltd |
Conjugado de enzimas terapéuticas
|
HUE064408T2
(hu)
|
2016-02-05 |
2024-03-28 |
Univ Emory |
Egyszálú vagy önkomplementer adeno-asszociált vírus 9 injekciója cerebrospinális folyadékba
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|